Company news
MacroGenics, Inc. news in 2022
MacroGenics, Inc.'s news releases, calls and decks from 2022, newest first.
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
November 16, 2022
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
November 2, 2022
MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call
October 25, 2022
Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies
October 16, 2022
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
August 7, 2022
MacroGenics Announces Date of Second Quarter 2022 Financial Results Conference Call
July 24, 2022
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
July 7, 2022
MacroGenics Announces Appointment of William Heiden to Board of Directors
May 22, 2022
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
May 2, 2022
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
April 24, 2022
MacroGenics Announces Executive Promotion
February 27, 2022
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
February 23, 2022
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
February 13, 2022